Evidence map›Paper›PMID 36134979›Full record

ArticleBioengineering (Basel, Switzerland)2022

Construction and In Vitro Evaluation of a Tumor Acidic pH-Targeting Drug Delivery System Based on

Yi Ma, Qiying Liu, Aihua Hu, Shoujin Jiang, Sijia Wang, Ran Liu, Kun Han, Jufang Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yi MaSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.
Qiying LiuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.
Aihua HuThe Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510140, China.
Shoujin JiangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.
Sijia WangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.
Ran LiuJiangsu Key Biotechnology Co., Ltd., Xuzhou 221100, China.
Kun HanJiangsu Key Biotechnology Co., Ltd., Xuzhou 221100, China.
Jufang WangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.ORCID 0000-0002-9908-1001
South China University of Technology · CNThird Affiliated Hospital of Guangzhou Medical University · CN

Funding

the Natural Science Foundation of Guangdong Province 2022A1515010716, 2019A1515011251
6 · The paper itself

Abstract

Synthetic nanocarriers are a promising therapeutic delivery strategy. However, these systems are often hampered by inherent disadvantages such as strong biotoxicity and poor biocompatibility. To overcome these issues, biological carriers with commonly used chemotherapy drugs have been developed. In this work, engineered bacterial ghosts (BGs) originated from probiotic

Indexed as

ATRAMbacterial ghostsdrug delivery systemLpp-OmpA displays systemphage α3

Identifiers

PMID36134979
PMCPMC9495381
OpenAlexW4294989759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.